MarketCap
Facebook
X
Telegram
Innate Pharma S.A. Retained Earnings | IPHA
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Innate Pharma S.A.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | -220 M | -156 M | -135 M | -152 M | -104 M | -116 M | -110 M | -90 M | -87.1 M | -6.98 M |
Annual performance
Select metrics to display
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -6.98 M | -220 M | -118 M |
Quarterly Retained Earnings Innate Pharma S.A.
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -135 M | - | - | - | -139 M | - | - | - | -104 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -104 M | -139 M | -126 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
-421 M | - | -6.63 % | $ 13.9 M |  USA |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Tenax Therapeutics
TENX
|
-367 M | $ 1.7 | 0.3 % | $ 66.7 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M | France |
 |
CureVac N.V.
CVAC
|
-1.4 B | - | - | $ 867 M |  Germany |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-325 M | - | 0.74 % | $ 768 M |  Israel |
 |
Abcam plc
ABCM
|
301 M | - | - | $ 4.9 B |  Britain |
 |
Rezolute
RZLT
|
-481 M | $ 4.09 | 1.74 % | $ 425 M | USA |
 |
Midatech Pharma plc
MTP
|
-156 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Tiziana Life Sciences PLC
TLSA
|
-145 M | $ 0.62 | 1.33 % | $ 66.1 M | Britain |
 |
MorphoSys AG
MOR
|
-1.01 B | - | 2.43 % | $ 254 M | Germany |
 |
Affimed N.V.
AFMD
|
-536 M | - | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
-578 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
-350 M | - | - | $ 12.5 M |  Belgium |
 |
Seer
SEER
|
-466 M | $ 1.61 | -0.31 % | $ 88.9 M | USA |
 |
Gracell Biotechnologies
GRCL
|
-1.63 B | - | - | $ 3.37 B | China |
 |
Shattuck Labs
STTK
|
-431 M | $ 5.04 | 3.61 % | $ 351 M | USA |
|
Silence Therapeutics plc
SLN
|
-305 M | $ 19.78 | -0.05 % | $ 2.8 B | Britain |
 |
Stoke Therapeutics
STOK
|
-498 M | $ 27.75 | 1.98 % | $ 1.64 B | USA |
 |
Sutro Biopharma
STRO
|
-978 M | $ 10.25 | 0.79 % | $ 87.1 M | USA |
 |
Soligenix
SNGX
|
-245 M | $ 0.32 | 0.37 % | $ 1.66 M | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
-13.8 B | $ 43.19 | 1.85 % | $ 49.5 B | Israel |
 |
China SXT Pharmaceuticals
SXTC
|
-34.2 M | $ 2.96 | 2.78 % | $ 2.01 M | China |
 |
Spruce Biosciences
SPRB
|
-289 M | $ 46.52 | -0.32 % | $ 35.7 M | USA |
 |
Takeda Pharmaceutical Company Limited
TAK
|
1.19 T | $ 20.83 | -0.38 % | $ 32.9 B |  Japan |
 |
Supernus Pharmaceuticals
SUPN
|
518 M | $ 29.29 | 1.88 % | $ 1.65 B | USA |
 |
Galapagos NV
GLPG
|
211 M | - | - | $ 1.83 B | Belgium |
 |
Savara
SVRA
|
-608 M | $ 5.03 | 2.24 % | $ 1.12 B | USA |
 |
Teligent, Inc.
TLGT
|
-121 M | - | -13.85 % | $ 16.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
-427 M | - | - | $ 2.91 B | USA |
 |
TG Therapeutics
TGTX
|
-1.08 B | $ 65.76 | 2.33 % | $ 9.49 B | USA |
 |
Aphria Inc.
APHA
|
-61.2 M | - | -0.45 % | $ 4.87 B |  Canada |
 |
Aerpio Pharmaceuticals, Inc.
ARPO
|
-147 M | - | -0.90 % | $ 104 M | USA |
 |
Chiasma, Inc.
CHMA
|
-348 M | - | -6.00 % | $ 238 M | USA |
 |
Trevi Therapeutics
TRVI
|
-330 M | $ 14.83 | -0.57 % | $ 2 B | USA |
 |
Adamas Pharmaceuticals, Inc.
ADMS
|
-505 M | - | - | $ 376 M | USA |
 |
AzurRx BioPharma, Inc.
AZRX
|
-62.7 M | - | 2.07 % | $ 34.4 M | USA |
 |
Cerecor Inc.
CERC
|
-178 M | - | -1.68 % | $ 283 M | USA |
 |
Constellation Pharmaceuticals, Inc.
CNST
|
-446 M | - | - | $ 1.63 B | USA |
 |
Auris Medical Holding Ltd.
EARS
|
-161 M | - | -1.77 % | $ 39.2 M |  Bermuda |
 |
Dicerna Pharmaceuticals, Inc.
DRNA
|
-638 M | - | 0.34 % | $ 2.98 B | USA |
 |
ERYTECH Pharma S.A.
ERYP
|
-73.3 M | - | 1.3 % | $ 27.7 M | France |
 |
GW Pharmaceuticals plc
GWPH
|
-896 M | - | - | $ 6.81 B | Britain |
 |
Kadmon Holdings, Inc.
KDMN
|
-444 M | - | - | $ 1.7 B | USA |
 |
Liminal BioSciences
LMNL
|
-1.08 B | - | - | $ 256 M | Canada |
 |
argenx SE
ARGX
|
-280 M | $ 977.91 | 0.65 % | $ 59.9 B |  Niderland |